Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
Browsing: Brain
Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
In this edition of The Onco’Zine Brief Peter Hofland talks with Catherine Ivy, the Founder and President of the Ben…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
David A. Reardon, MD Dana-Farber Cancer Institute discusses What is the rationale in combining these agents together? – INO-5401 and…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food…
Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July…
Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the…
Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this…
Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth discusses the patients with newly diagnosed glioblastoma, initial experience with scalp saving…
Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth answers common questions asked on the patients with newly diagnosed glioblastoma, initial…
Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co.,…
Philadelphia, PA (March 26, 2020) – Oncoceutics, Inc. announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a…
Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma…
Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma…
Philadelphia, PA (January 27, 2020) – Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics explains how this is going to affect clinicians today and what clinicians should…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers what data has come out of the trial? _________ Oncoceutics, Inc. announced…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers how can we get access to this drug for glioblastoma? ___________ Oncoceutics,…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses what’s next in ONC201 in adult recurrent glioblastoma. __________ Oncoceutics, Inc. announced…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses the clinical efficacy of weekly ONC201 in adult recurrent glioblastoma. ________ Oncoceutics,…
Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center…
The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in…
Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase…
Akash J. Patel of @bcmhouston answers meningioma molecular profiling reliably predicts tumor recurrence: how does this help us? ________ Read…
Akash J. Patel of @bcmhouston explains meningioma molecular profiling reliably predicts tumor recurrence. __________ Read here: https://www.eurekalert.org/pub_releases/2019-10/bcom-mmp100719.php
Kailin Yang, MD of Cleveland Clinic answers how this will affect clinicians today and questions asked by his colleagues. _______…
Kailin Yang, MD of Cleveland Clinic discusses targeting metabolic reprogramming to radiosensitize glioblastoma stem cells. _________ Inhibiting two critical steps…
Philadelphia, PA (September 16, 2019) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates National Childhood Cancer Awareness Month…
Philadelphia, PA (September 10, 2019) – Oncoceutics, Inc. announced a scientific publication in the Journal of Neuro-Oncology describing a complete…
Philadelphia, PA (August 26, 2019) – Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Why Does This Subset Of Patients Respond To ONC201: It Appears To…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Other Suitable Combinations For This Agent That Could Help More People: Which…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median…
Michael Ciesielski, Phd @mjciesielski Of Roswell Park Comprehensive Cancer Center Discusses Latest Data On SurVaxM Vaccine: Doubled Progression Free Period,…
Hope Rugo, M.D., University Of California San Francisco discusses Talazoparib First Line Treatment. At ESMO Oncology Conference – Munich, Germany…
Hope Rugo, M.D., University Of California San Francisco discusses IMpassion130, Solar-1 Trial Data. At ESMO Oncology Conference – Munich, Germany…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Wolfgang Wick, MD, of the…
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas…